Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference30 articles.
1. Camidge DR, Dziadziuszko R, Peters S, Mok T, Noe J, Nowicka M, Gadgeel SM, Cheema P, Pavlakis N, de Marinis F, Cho BC, Zhang L, Moro-Sibilot D, Liu T, Bordogna W, Balas B, Müller B, Shaw AT. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study. J Thorac Oncol. 2019;14:1233–43. https://doi.org/10.1016/j.jtho.2019.03.007.
2. Mok T, Shaw AT, Camidge RD, Gadgeel SM, Rosell R, Dziadziuszko R, et al. Final PFS, updated OS and safety data from the randomised, phase III ALEX study of alectinib (ALC) versus crizotinib (CRZ) in untreated advanced ALk + NSCLC. Ann Oncol. 2019;30(Suppl_5):V602–60.
3. Camidge DR, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Lee J-S, Hochmair MJ, Li JY-C, Chang G-C, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim D-W, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379:2027–39. https://doi.org/10.1056/NEJMoa1810171.
4. Camidge R, Kim HR, Ahn M-J, Yang JC-H, Han J-Y, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim D-W, Griesinger F, Felip E, Califano R, Spira A, Gettinger S, Tiseo M, Ni Q, Zhang P, Popat S. Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK + NSCLC: updated results from the phase III ALTA-1L trial. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz446.
5. Duruisseaux M, Besse B, Cadranel J, Pérol M, Mennecier B, Bigay-Game L, Descourt R, Dansin E, Audigier-Valette C, Moreau L, Hureaux J, Veillon R, Otto J, Madroszyk-Flandin A, Cortot A, Guichard F, Boudou-Rouquette P, Langlais A, Missy P, Morin F, Moro-Sibilot D. Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study. Oncotarget. 2017;8:21903–17. https://doi.org/10.18632/oncotarget.15746.
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献